share_log

Contrasting Better Therapeutics (BTTX) and The Competition

Contrasting Better Therapeutics (BTTX) and The Competition

对比 Better Therapeutics (BTTX) 和竞争对手
Financial News Live ·  2022/12/22 03:51

Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 public companies in the "Health services" industry, but how does it contrast to its peers? We will compare Better Therapeutics to related businesses based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.

Better Treateutics(纳斯达克代码：BTTX-GET Rating)是“健康服务”行业的33家上市公司之一，但它与同行有何不同？我们将根据其估值、机构所有权、股息、收益、分析师建议、风险和盈利能力，将Better Treeutics与相关业务进行比较。

Earnings & Valuation

收益与估值

This table compares Better Therapeutics and its peers gross revenue, earnings per share and valuation.

此表比较了Better Treateutics及其同行的毛收入、每股收益和估值。

Get
到达
Better Therapeutics
更好的治疗学
alerts:
警报：
Gross Revenue Net Income Price/Earnings Ratio
Better Therapeutics $10,000.00 -$40.33 million -0.73
Better Therapeutics Competitors $1.36 billion -$98.47 million 34.40
总收入 净收入 市盈率
更好的治疗学 $10,000.00 -4,033万元 -0.73
Better Treateutics的竞争对手 13.6亿美元 -9,847万元 34.40

Better Therapeutics' peers have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Better Treateutics的同行有更高的收入，但收入比Better Treateutics低。Better Treateutics的市盈率低于同行，这表明它目前比行业内的其他公司更负担得起。

Institutional & Insider Ownership

机构与内部人持股

7.5% of Better Therapeutics shares are held by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are held by institutional investors. 59.4% of Better Therapeutics shares are held by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Better Treateutics 7.5%的股份由机构投资者持有。相比之下，所有“健康服务”公司48.6%的股份由机构投资者持有。Better Treateutics 59.4%的股份由公司内部人士持有。相比之下，所有“健康服务”公司21.6%的股份由公司内部人士持有。强大的机构持股表明，对冲基金、捐赠基金和大型基金管理公司相信，一家公司的长期表现将好于大盘。

Risk and Volatility

风险和波动性

Better Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' peers have a beta of 1.19, meaning that their average share price is 19% more volatile than the S&P 500.

Better Treateutics的贝塔系数为1.36，这意味着其股价的波动性比标准普尔500指数高36%。相比之下，Better Treateutics的贝塔系数为1.19，这意味着它们的平均股价波动性比标准普尔500指数高19%。

Profitability

盈利能力

This table compares Better Therapeutics and its peers' net margins, return on equity and return on assets.

此表比较了Better Treeutics及其同行的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
Better Therapeutics N/A -200.73% -114.68%
Better Therapeutics Competitors -325.87% -676.77% -37.31%
净利润率 股本回报率 资产回报率
更好的治疗学 不适用 -200.73% -114.68%
Better Treateutics的竞争对手 -325.87% -676.77% -37.31%

Analyst Ratings

分析师评级

This is a summary of current ratings for Better Therapeutics and its peers, as provided by MarketBeat.com.

这是由MarketBeat.com提供的Better Treateutics及其同行的当前评级摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Better Therapeutics 0 0 2 0 3.00
Better Therapeutics Competitors 7 131 278 0 2.65
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
更好的治疗学 0 0 2 0 3.00
Better Treateutics的竞争对手 7 131 278 0 2.65

Better Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 845.95%. As a group, "Health services" companies have a potential upside of 160.81%. Given Better Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Better Therapeutics is more favorable than its peers.

Better Treateutics目前的共识目标价为14.00美元，暗示潜在上涨845.95%。作为一个整体，“健康服务”公司有160.81%的潜在上行空间。鉴于Better Treeutics更高的共识评级和更高的可能上行空间，研究分析师显然认为Better Treateutics比其同行更有利。

Summary

摘要

Better Therapeutics beats its peers on 8 of the 12 factors compared.

Better Treateutics在比较的12个因素中有8个超过了同行。

About Better Therapeutics

关于Better Treatetics

(Get Rating)

(获取评级)

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Better Treateutics，Inc.，一家处方数字治疗公司，开发了一种认知行为疗法，以解决心脏代谢性疾病的原因。该公司开发基于软件的处方数字疗法平台，用于治疗糖尿病、心脏病和其他心脏代谢疾病。其临床开发候选药物旨在治疗心脏代谢性疾病，包括2型糖尿病、高血压、高脂血症、非酒精性脂肪性肝病、非酒精性脂肪性肝炎和慢性肾脏疾病。该公司的主要候选产品是BT-001，这是一种治疗2型糖尿病的研究PDT平台。Better Treateutics，Inc.成立于2015年，总部位于加利福尼亚州旧金山。

Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每天收到更好的治疗新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对Better Treateutics和相关公司的评级的每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发